Clinical trials depend on willing and engaged participants, yet participation can be demanding. Frequent site visits, complex study information, long consent forms, travel requirements, unfamiliar procedures, and language barriers can make trials difficult to navigate. Patient centricity addresses these challenges by making patients’ needs, experiences, and perspectives part of trial planning and execution rather than treating them as an afterthought.
A patient-centric approach can help sponsors and contract research organizations (CROs) reduce unnecessary burden, improve recruitment and retention, and generate evidence that better reflects patient priorities. It also aligns with growing regulatory interest in incorporating patient perspectives into medical product development, including the Food and Drug Administration (FDA) Patient-Focused Drug Development (PFDD) initiative and the principles reflected in the International Council for Harmonisation’s ICH E6(R3) guideline.
What Is Patient Centricity in Clinical Trials?
Patient centricity in clinical trials means designing and conducting research around the needs, preferences, experiences, and realities of the people who participate in it.
It should influence decisions throughout the trial lifecycle:
- Study design: Considering patient priorities when selecting endpoints, procedures, eligibility criteria, and visit schedules.
- Recruitment: Providing clear information and making participation accessible to appropriate populations.
- Participation: Reducing unnecessary visits, procedures, travel, waiting times, and administrative demands.
- Communication: Providing information that participants can understand and use to make informed decisions.
- Follow-up: Keeping participants appropriately informed about study progress, results, and next steps.
Patient centricity is closely related to patient engagement, but the two are not identical. Patient engagement refers to actively involving patients and their representatives in research activities and decisions. Patient centricity is broader. It means consistently incorporating patient needs into how the trial is designed and delivered. Patient engagement is therefore one important way to achieve patient centricity.
How to Implement Patient Centricity in Clinical Trials
1. Involve Patients Early in Trial Planning
Patient input is most valuable when it can influence decisions. Sponsors can engage patient advisory groups, advocacy organizations, caregivers, or representative participants before finalizing the protocol.
Ask practical questions such as:
- Is the visit schedule realistic?
- Which procedures could be particularly difficult or disruptive?
- Is the proposed endpoint meaningful to patients?
- What might prevent someone from enrolling or completing the study?
- What information would patients need before deciding to participate?
The objective is not simply to collect opinions. Feedback should be assessed, incorporated where appropriate, and documented so that patient input has a clear connection to trial decisions.
2. Reduce Patient Burden
Every activity required of a participant should be examined from the patient’s perspective. Where scientifically and ethically appropriate, sponsors can consider fewer site visits, flexible scheduling, remote assessments, home-based procedures, or digital data collection.
Technology can help, but it is not automatically patient-centric. A digital platform that is difficult to use or inaccessible to certain populations may introduce new barriers. The right solution depends on the study, patient population, resources, and local context.
Reducing burden should therefore mean making participation genuinely more manageable, not simply moving trial activities from the clinic to a digital platform.
3. Provide Clear and Accessible Patient Communications
Patient-facing materials should explain the trial without unnecessary scientific or regulatory complexity. Informed consent forms, patient information sheets, diaries, questionnaires, recruitment materials, and study instructions should use clear language and a logical structure.
Accessibility goes beyond readability. Participants need to understand the study’s purpose, procedures, potential benefits and risks, responsibilities, and their right to make a voluntary decision. ICH E6(R3) emphasizes providing relevant information in a way that supports participant understanding during informed consent.
Clear communication can also support retention. Participants who understand what is expected of them are better positioned to manage study requirements and raise concerns when problems arise.
4. Translate and Localize Patient-Facing Materials
For global clinical trials, English-language materials cannot simply be translated word for word and considered patient-centric. Participants need information in a language and form they can understand within their cultural and healthcare context. Localization considers factors such as terminology, cultural expectations, literacy, healthcare practices, units of measurement, and how health concepts are expressed in the target market.
Some materials require additional linguistic validation. This is especially important for patient-reported outcomes (PROs), clinical outcome assessments (COAs), and quality-of-life questionnaires, where subtle wording differences can affect how participants interpret and answer questions.
EC Innovations provides specialized clinical trial translation services for global clinical programs, including patient-facing materials, linguistic validation, cultural adaptation, and in-country review, as needed.
5. Collect and Act on Patient Feedback
Patient centricity should continue after recruitment begins. Sponsors and research sites can use surveys, interviews, advisory boards, participant support channels, and site feedback to identify problems during the study.
The important step is acting on what is learned. If participants consistently report difficulties with scheduling, procedures, communication, or study technology, the team should determine whether it can make an appropriate adjustment while maintaining scientific integrity and regulatory compliance.
Conclusion
Patient centricity is not a single intervention. It is an ongoing approach to clinical trial design and management that considers the participant experience alongside scientific, operational, and regulatory requirements.
For global studies, language and culture are particularly important. Participants cannot make informed decisions or meaningfully engage with research when essential information is difficult to understand or culturally inappropriate. Translation, localization, linguistic validation, and in-country review should therefore be considered during trial planning rather than treated as administrative tasks at the end of the process.
By involving patients early, reducing unnecessary burden, improving communication, and responding to participant feedback, sponsors and CROs can develop trials that are more accessible, practical, and aligned with patient needs.
Partner with EC Innovations
Making clinical trials more patient-centric requires communication that is accurate, accessible, and appropriate for each population. For global studies, that includes getting translation and localization right.
EC Innovations supports global clinical programs with specialized life sciences translation and localization services. From multilingual clinical trial documentation and patient-facing materials to linguistic validation, cultural adaptation, and in-country review, our teams help life sciences organizations communicate accurately and effectively across markets.
Contact EC Innovations to discuss your clinical trial translation and localization requirements.
